References
- Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–2934.
- Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol. 2015;26:1547–1573.
- Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park, N.Y.). 2013;27:80–81. 149.
- Bentley TGK, Cohen JT, Elkin EB, et al. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health. 2017;20:200–205.
- Chouaid C, Borget I, Braun E, et al. French health technology assessment of antineoplastic drugs indicated in the treatment of solid tumours: perspective for future trends. Target Oncol. 2016;11:515–534.
- Oudard S, Courbon F. Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer. Ann Oncol. 2017;28:421–426.
- Akehurst RL, Abadie E, Renaudin N, et al. Variation in health technology assessment and reimbursement processes in Europe. Value Health. 2017;20:67–76.
- Pujolras LM, Cairns J. Why do some countries approve a cancer drug and others don’t?. J Cancer Policy. 2015;4:21–25.
- Kanavos P, Nicod E, van Den Aardweg S, et al. The impact of health technology assessments: an international comparison. Euro Obs. 2010;12:1–7.
- Aggarwal A, Fojo T, Chamberlain C, et al. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol. 2017;28:1738–1750.
- Vivot A, Jacot J, Zeitoun J-D, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28:1111–1116.
- Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–1236.
- Prasad V, McCabe C, Mailankody S. Low-value approvals and high prices might incentivize ineffective drug development. Nat Rev Clin Oncol. 2018;15:399–400.
- Drugs@FDA: FDA Approved Drug Products [Internet]. [ cited 2018 May 17]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
- Del Paggio JC, Sullivan R, Schrag D, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 2017;18:887–894.
- Haute Autorité de Santé - TAFINLAR (dabrafenib), inhibiteur de tyrosine kinase [Internet]. [ cited 2018 May 11]. Available from: https://www.has-sante.fr/portail/jcms/c_1742463/fr/tafinlar-dabrafenib-inhibiteur-de-tyrosine-kinase.
- Wild C, Grössmann N, Bonanno PV, et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol. 2016;27:2134–2136.
- Grande M, Fernandez J, Dahmani B, et al. 1436O_PRHow to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS. Ann Oncol. Internet]. 2017 cited 2018 May 17; 28. Available from: https://academic.oup.com/annonc/article/28/suppl_5/mdx440.064/4109976
- Banzi R, Gerardi C, Bertele’ V, et al. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med. 2015;26:572–584.
- Booth CM, Del Paggio JC. Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol. 2017;14:135–136.
- Grössmann N, Del Paggio JC, Wolf S, et al. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit. Eur J Cancer. 2017;82:66–71.
- Gonçalves A, Maraninchi D, Vernant J-P. Challenging the soaring price of cancer medicines: a call for equity and transparency. Ann Oncol. 2016;27:1812–1813.
- Cherny NI, Dafni U, Bogaerts J, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann. Oncol. 2017;28:2340–2366.